Tagra Biotechnologies

Company Overview

Snapshot

Founded in June 1998 by Ron Folman, Tagra Biotechnologies operates with 11–50 employees. The company specializes in microencapsulation technology for cosmetic ingredients, a field it has advanced through strategic distribution agreements, including one with Azelis in August 2017 to strengthen its position in Asia Pacific, particularly China.

Business overview

Tagra Biotechnologies develops and manufactures cosmetic ingredients, leveraging its proprietary microencapsulation technology and skin delivery systems. The company focuses on overcoming technical challenges in cosmetic formulation to create innovative beauty products. Its ingredients are globally compliant, free of common irritants, Halal certified, non-nano-sized, and not tested on animals. Tagra's technology enables visual and sensory effects like color and texture transitions, alongside stabilized active ingredients for improved anti-aging benefits, serving the broader Health Tech & Life Sciences sector, specifically within cosmetic materials and pharmaceuticals.

Strategic signal

In February 2020, Tagra Biotechnologies signed an agreement with Caldic UK Ltd, indicating a strategic expansion of its distribution network within the European market. This partnership suggests a continued focus on broadening market reach and accessibility for its microencapsulation technologies and cosmetic ingredients, signaling potential growth in its commercial footprint.

Company Intelligence Q&A

When was Tagra Biotechnologies founded and by whom?

Tagra Biotechnologies was founded in June 1998 by Ron Folman, who serves as the Founder & CEO.

What significant distribution agreement did Tagra Biotechnologies secure in Asia?

In August 2017, Azelis strengthened its ties with Tagra Biotechnologies through an exclusive distribution agreement in China, enhancing Tagra's market position in the Asia Pacific region.

What recent partnership did Tagra Biotechnologies establish in the UK?

In February 2020, Caldic UK Ltd signed an agreement with Tagra Biotechnologies, indicating an expansion of the company's distribution channels in the United Kingdom.

How does Tagra Biotechnologies improve cosmetic microencapsulation?

In April 2019, Tagra Biotechnologies highlighted its efforts in improving cosmetic microencapsulation to create new user experiences, focusing on visual and sensory effects and stabilized active delivery.